Articles tagged "Survival"

2022 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV⁺) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
V. Dharnidharka¹, D. Thirumalai², U. Jaeger³, W. Zhao², D. Dierickx⁴, P. Xun², P. Minga⁵, A. Sawas⁶, N. Sadetsky⁷, P. Chauvet⁸, E. Sundaram⁹, A. Barlev⁷, H. Zimmermann¹⁰, R. U. Trappe¹⁰
¹Washington University School of Medicine/St Louis Children’s Hospital, St Louis, MO, ²Atara Biotherapeutics, Thousand Oaks, CA, ³Medical University of Vienna, Vienna, Austria, ⁴Universitair Ziekenhuis Leuven, Leuven, Belgium, ⁵Niguarda Ca’ Granda Hospital, Milan, Italy, ⁶Herbert Irving Comprehensive Cancer Center, Department of Medicine, CUMC, New York, NY, ⁷Atara Biotherapeutics, South San Francisco, CA, ⁸Service des Maladies du Sang, CHU Lille, Lille, France, ⁹Nashville Biosciences, Nashville, TN, ¹⁰DIAKO Bremen, Bremen, Germany
*Purpose: EBV+ PTLD patients (pts) following SOT who fail rituximab + chemotherapy (CT) have poor outcomes with limited treatment options. Published data on clinical outcomes…
2022 American Transplant Congress
Fontan versus Non-Fontan Combined Heart-Liver Transplantation: Proceed but Cautiously
I. A. Ziogas, W. K. Wu, M. Izzy, A. Shingina, C. Benson, K. L. Mishra, A. S. Shah, N. L. Do, W. G. McMaster, J. N. Menachem, S. P. Alexopoulos
Vanderbilt University Medical Center, Nashville, TN
*Purpose: Combined heart-liver transplantation (CHLT) is increasing, corresponding with a growing prevalence of Fontan-associated end-organ damage. We aimed to describe our contemporary institutional experience with…
2022 American Transplant Congress
Cutaneous Angiosarcoma in Solid Organ Transplant Recipients – Novel Case & Review of the Literature
S. M. Elzein, R. R. Caplan
Houston Methodist Hospital, Houston, TX
*Purpose: Cutaneous angiosarcoma, a rare and extremely aggressive malignant neoplasm, has been described in fewer than twenty-five solid organ transplant recipients to date. Secondary, or…
2022 American Transplant Congress
Influence of the Competing Risk of Recipient Death on the Risk Estimation of Kidney Transplant Failure
M. Coemans¹, G. Verbeke², B. Döhler³, C. Süsal³, M. Naesens¹
¹Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium, ²Leuven Biostatistics and Statistical Bioinformatics Centre, Leuven, Belgium, ³Heidelberg University Hospital, Heidelberg, Germany
*Purpose: Prognostic models for kidney transplant failure are often based on methods that censor for recipient death. Death is a competing event biasing the risk…
2022 American Transplant Congress
Steatosis Following Liver Transplantation for Nonalcoholic Steatohepatitis is Associated with a Higher Rate of Cardiovascular Complications
W. Alhamoudi¹, S. Alqahtani², K. Bzeizi², A. Albenmousa², Y. Saleh², D. Broering², S. Alghamdi²
¹Medicine, King Saud University, Riyadh, Saudi Arabia, ²Liver Transplantation, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
*Purpose: Cirrhosis secondary to Nonalcoholic Steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) worldwide. Objectives: to evaluate the prevalence of…
2022 American Transplant Congress
Area Deprivation Index is Associated with Worse Patient Survival Following Adult Liver Transplantation
J. Hendele¹, J. Perkins², J. Nichols³, A. Dick¹
¹Division of Transplant Surgery, Department of Surgery, University of Washington, Seattle, WA, ²Clinical and Bio-Analytics Transplant Laboratory (CBATL), University of Washington, Division of Transplant Surgery, Department of Surgery, Seattle, WA, ³School of Medicine, University of Washington, Seattle, WA
*Purpose: Area Deprivation Index (ADI) has been utilized as a granular measure of local socioeconomic status for nearly two decades. This study is the first…
2022 American Transplant Congress
Characterizing Outcomes of Patients with Colorectal Liver Metastases (CRLM) Undergoing Liver Transplantation (LT) Evaluation
E. Takoushian¹, E. Brandon¹, B. Samstein², K. Halazun²
¹Liver Transplantation, New York Presbyterian Weill Cornell, New York, NY, ²Weill Cornell Medical Center, New York, NY
*Purpose: LT is a novel therapy for patients with unresectable CRLM. 5 year survival using LT appears to be significantly better than systemic chemotherapy in…
2022 American Transplant Congress
Alemtuzumab and Basilximab Induction Therapy in Lung Transplantation
M. Furukawa, E. Chan, P. G. Sanchez
Cardiothoracic Surgery, UPMC, Pittsburgh, PA
*Purpose: Induction therapy is used in about more than 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guideline…
2022 American Transplant Congress
Adult-to-Adult Living Donor Liver Transplantation in Acute Liver Failure – Do Outcomes Justify the Risks?
A. Shingina¹, I. A. Ziogas², P. Vutien³, E. Uleryk⁴, E. Renner⁵, M. P. Bhat⁶, J. Tinmouth⁴, J. Kim⁷
¹Vanderbilt University, Nashville, TN, ²Division of Hepatobiliary Surgery and Liver Transplantation, Vanderbilt University Medical Center, Nashville, TN, ³University of Washington Medical Center, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵University of Manitoba, Saskatchewan, MB, Canada, ⁶Multi-Organ Transplant, UHN, Toronto, ON, Canada, ⁷Toronto General Hospital, Toronto, ON, Canada
*Purpose: Living-donor Liver Transplantation(LDLT) has emerged as a safe and effective alternative in children and adults with pre-existing liver diseases. Utilization of LDLT for patients…
2022 American Transplant Congress
Retransplantation in a High-Volume Institution: Historical, Socioeconomic and Survival Trends
D. von Ahrens, O. Sulimani, M. Holzner, M. Akhtar, S. Florman, A. Arvelakis
The Mount Sinai Hospital, New York, NY
*Purpose: Retransplantation for liver allograft failure is a challenge within the field. The evolution of organ allocation policy from Child to MELD in 2002 and…

1
2
3
…
66
Next Page »